Comparison of the effects of tofacitinib and adalimumab on transcolonoscopic ph and calprotectin levels in patients with ulcerative colitis

0Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

OBJECTIVE: The aim: To investigate the transcolonoscopic pH-metry and calprotectin in patients with ulcerative colitis. PATIENTS AND METHODS: Materials and methods: the research included 110 patients both male and female between the ages of 18 to 75 years old, who were treated for UC of medium and severe activity, in active phase. All patients were divided into 3 groups. The first group received standard therapy (ST; n=50), the second group received adalimumab (ADA; n=32), and the third group was treated with tofacitinib (TOF; n=28). The control group consisted of healthy individuals between the ages of 18 and 65 years old. RESULTS: Results: UC patients had lower pH levels in all sections of the large intestine, compared to the control group (р<0,05). Calprotectin level is a better predictor of the course of the disease. CONCLUSION: Conclusions:Tofacitinib, compared to adalimumab and budesonide, has better influence on clinical, endoscopic and laboratory parameters of UC.

Cite

CITATION STYLE

APA

Varvarynets, A. V., Chubirko, K. I., Chopey, I. V., Hnepa, Y. Y., & Kurakh, A. V. (2020). Comparison of the effects of tofacitinib and adalimumab on transcolonoscopic ph and calprotectin levels in patients with ulcerative colitis. Wiadomosci Lekarskie (Warsaw, Poland : 1960), 73(3), 441–443. https://doi.org/10.36740/wlek202003105

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free